GlassScriptPhysician profile
Ashton N Thomas
NPI 1063198299
$4,314.54
in general payments reported to CMS, 2019-2025
43 companies · $2,421 in 2025
The $2,421 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $640 · 2024: $1,253 · 2025: $2,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.54 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $729.59 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $524.05 | 2023-2025 | |
| Daiichi Sankyo INC. | $446.47 | 2023-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $306.01 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $230.30 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Stemline Therapeutics INC. | $176.52 | 2023-2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $121.54 | 2023-2025 | Qinlock |
| Regeneron Healthcare Solutions, INC. | $115.45 | 2023-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $107.30 | 2025 | |
| Aveo Pharmaceuticals, INC. | $97.45 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $91.58 | 2023-2025 | Onivyde, Somatuline Depot |
| Pharmacosmos Therapeutics INC. | $91.26 | 2023-2025 | Monoferric |
| Beigene USA, INC. | $79.30 | 2024-2025 | Brukinsa |
| Pharmaessentia USA Corporation | $79.10 | 2025 | Besremi |
| Genmab U.S., INC. | $74.93 | 2024-2025 | Epkinly, Tivdak |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $74.56 | 2023-2025 | Polivy, Phesgo, Tecentriq |
| Alexion Pharmaceuticals, INC. | $72.73 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $66.82 | 2024-2025 | |
| Glaxosmithkline, LLC. | $65.68 | 2024-2025 | Jemperli, Zejula |
| Celgene Corporation | $56.41 | 2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $55.36 | 2024-2025 | Alunbrig, Fruzaqla |
| Astellas Pharma US INC | $54.57 | 2023-2025 | Vyloy |
| Emd Serono, INC. | $49.45 | 2023-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $48.14 | 2023-2024 | |
| Exelixis INC. | $46.01 | 2023-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.03 | 2024-2025 | Gilotrif |
| Abbvie INC. | $39.91 | 2024-2025 | |
| Beone Medicines USA, INC. | $36.39 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $36.10 | 2024-2025 | Trodelvy |
| Kite Pharma, INC. | $33.70 | 2024 | Yescarta |
| Lilly USA, LLC | $31.06 | 2025 | Retevmo |
| Tersera Therapeutics LLC | $30.15 | 2025 | Zoladex |
| Syndax Pharmaceuticals, INC. | $25.19 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $22.11 | 2025 | Opdivo |
| Recordati_rare_diseases_inc. | $20.37 | 2025 | Sylvant |
| Tactile Systems Technology INC | $18.69 | 2024 | Flexitouch Plus, Entre Plus |
| Dendreon Pharmaceuticals LLC | $18.42 | 2025 | Provenge |
| Agios Pharmaceuticals, INC. | $18.35 | 2025 | Pyrukynd |
| Fennec Pharmaceuticals, INC. | $17.52 | 2025 | Fyarro |
| Sirtex Medical INC | $16.56 | 2024 | Sir-Spheres Microspheres |
| Seagen INC. | $15.37 | 2023 | Tukysa |
| Karyopharm Therapeutics INC. | $14.81 | 2023 | Xpovio |
| Geron Corporation | $14.23 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.